Calcineurin inhibitors and cardiac hypertrophy

There has been much debate over whether the immunosuppressive agent, cyclosporin A (CsA), can prevent the development of cardiac hypertrophy. Force et al discuss studies that have found that activated calcineurin (and NF-AT3) could cause hypertrophy and that CsA could prevent this hypertrophy.

Saved in:
Bibliographic Details
Published inThe Lancet (British edition) Vol. 353; no. 9161; pp. 1290 - 1292
Main Authors Force, Thomas, Rosenzweig, Anthony, Choukroun, Gabriel, Hajjar, Roger
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 17.04.1999
Elsevier Limited
Subjects
Animals
Calcineurin - physiology
Calcineurin Inhibitors
Cardiomegaly - prevention & control
Cyclosporine - pharmacology
Drug therapy
Heart
Humans
Immunosuppressive Agents - pharmacology
Medical disorders
Mice
Mice, Transgenic
Preventive medicine
Online AccessGet full text

Cover

More Information
Summary:There has been much debate over whether the immunosuppressive agent, cyclosporin A (CsA), can prevent the development of cardiac hypertrophy. Force et al discuss studies that have found that activated calcineurin (and NF-AT3) could cause hypertrophy and that CsA could prevent this hypertrophy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(99)90016-8